BioCentury
ARTICLE | Finance

Fresh off Lilly deal, AbCellera readies to deploy $105M to streamline antibody-based R&D

May 28, 2020 2:20 AM UTC

Days after expanding a deal with Eli Lilly, AbCellera has raised $105 million in a series B round to speed its partners’ path to the clinic by expanding its own R&D capabilities.

CEO Carl Hansen told BioCentury that AbCellera Biologics Inc. will use the untranched round to “double down on capacity, on people and on technology.” ...

BCIQ Company Profiles

AbCellera Biologics Inc.